Form 4: Agios Pharmaceuticals CFO Cecilia Jones Reports Stock Transactions

Cecilia Jones, CFO of Agios Pharmaceuticals, reports acquisition and disposal of company stock and derivative securities, including stock options and restricted stock units.

Summary

• Cecilia Jones, the Chief Financial Officer of Agios Pharmaceuticals, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
• On March 1, 2024, she acquired 2,000 shares of common stock through the company's employee stock purchase plan at a price of $0.
• Also on March 1, 2024, she was granted 17,000 restricted stock units and options to purchase 60,000 shares of common stock.
• On March 5, 2024, she disposed of 672 shares of common stock at a price of $32.57 per share to cover tax withholding obligations related to the vesting of performance share units.
• Following these transactions, Jones directly owns 14,840 shares of common stock, 17,000 restricted stock units, and options to purchase 60,000 shares.
• The restricted stock units granted on March 1, 2024, will vest in three equal annual installments beginning on March 1, 2025.
• The stock options granted on March 1, 2024, vest as to 25% on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There is no indication of unusual or concerning activity.

Positives

• The acquisition of shares through the employee stock purchase plan demonstrates the CFO's investment in the company's future.

Negatives

• The sale of shares to cover tax obligations, while routine, slightly reduces the CFO's direct holdings.

Future Outlook

The reported transactions reflect ongoing compensation and ownership adjustments for the CFO, with vesting schedules extending into the future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common compensation practices for executives in the pharmaceutical industry, aligning their interests with those of shareholders.
• Vesting schedules, such as the three-year annual installments for restricted stock units and the combination of cliff and monthly vesting for stock options, are typical in executive compensation packages.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the CFO's stake in the company.
• The vesting schedules for stock options and restricted stock units incentivize the CFO to contribute to the company's long-term success.

Key Dates